Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Neurobiol Dis ; 23(3): 725-30, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16876425

RESUMEN

Children with hereditary severe hyperhomocysteinemia present with a variety of neurological impairment, and mild hyperhomocysteinemia has been associated with neurodegeneration in the elderly. The link of hyperhomocysteinemia to neurological dysfunction is unknown. We investigated mitochondrial mechanisms of homocysteine (HCys) neurotoxicity in rat dopaminergic pheochromocytoma cells, human neuroblastoma cells and primary rat cerebellar granule neurons. HCys dose dependently impaired cytochrome c oxidase (COX) activity as well as stability and induced reactive oxygen species and apoptotic cell death. We found that HCys binds the COX cofactor Cu(2+), and Cu(2+) supplementation prior to HCys treatment preserved COX activity and prevented cell death. The Cu(2+) chelating action of HCys and impairement of COX activity represent novel mechanisms of HCys neurotoxicity, which might be preventable by supplementation of Cu(2+).


Asunto(s)
Encéfalo/metabolismo , Cobre/metabolismo , Deficiencia de Citocromo-c Oxidasa/metabolismo , Hiperhomocisteinemia/metabolismo , Enfermedades Neurodegenerativas/metabolismo , Neuronas/metabolismo , Animales , Animales Recién Nacidos , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Encéfalo/fisiopatología , Células Cultivadas , Quelantes/metabolismo , Quelantes/farmacología , Cobre/farmacología , Relación Dosis-Respuesta a Droga , Complejo IV de Transporte de Electrones/antagonistas & inhibidores , Complejo IV de Transporte de Electrones/metabolismo , Homocisteína/metabolismo , Homocisteína/toxicidad , Humanos , Hiperhomocisteinemia/complicaciones , Hiperhomocisteinemia/fisiopatología , Síndrome del Pelo Ensortijado/metabolismo , Síndrome del Pelo Ensortijado/fisiopatología , Enfermedades Neurodegenerativas/genética , Enfermedades Neurodegenerativas/fisiopatología , Neuronas/efectos de los fármacos , Neuronas/patología , Fármacos Neuroprotectores/metabolismo , Fármacos Neuroprotectores/farmacología , Células PC12 , Ratas
2.
Exp Neurol ; 201(2): 293-300, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16740261

RESUMEN

Magnetic resonance imaging (MRI) has provided important information in characterizing amyotrophic lateral sclerosis (ALS) in humans and in animal models. A frequently used animal model to study mechanisms of pathogenesis and the efficacy of drugs in ALS is a transgenic mouse over-expressing the human mutated G93A-superoxide dismutase 1 (G93A-SOD1). In our study, we applied MRI to find suitable progression markers, which can be used to monitor the development of ALS and to evaluate therapeutic approaches at early stages of the disease. Therefore, we generated parameter maps of the spin-spin relaxation time (T2) and the apparent diffusion coefficient (ADC) starting at day 70 after birth, i.e., before motor scores decline around day 90. Depending on the progression of the disease, G93A-SOD1 mice showed significantly increased values of T2 in the brain stem motor nuclei Nc. V (trigeminal nucleus), VII (facial nucleus), and XII (hypoglossal nucleus), and spinal cord compared to non-transgenic wild-type mice and transgenic mice over-expressing the non-mutated wild-type human SOD1 (tg-SOD1). Similar effects in these motor nuclei were revealed by ADC mapping. Furthermore, in the upper spinal cord, a dorsal-ventral difference with significantly higher T2 values in the ventral part was demonstrated by T2 mapping. While both T2 and ADC might prove useful as progression markers and enable the longitudinal non-invasive evaluation of ALS in G93A-SOD1 mice, the potential is limited by age-dependent effects in case of ADC mapping.


Asunto(s)
Esclerosis Amiotrófica Lateral/fisiopatología , Encéfalo/fisiopatología , Enfermedad de la Neurona Motora/fisiopatología , Superóxido Dismutasa/genética , Esclerosis Amiotrófica Lateral/genética , Esclerosis Amiotrófica Lateral/patología , Análisis de Varianza , Animales , Encéfalo/metabolismo , Encéfalo/patología , Modelos Animales de Enfermedad , Humanos , Imagen por Resonancia Magnética/métodos , Masculino , Ratones , Ratones Endogámicos , Ratones Transgénicos , Corteza Motora/metabolismo , Corteza Motora/patología , Corteza Motora/fisiopatología , Enfermedad de la Neurona Motora/genética , Enfermedad de la Neurona Motora/patología , Neuronas Motoras/metabolismo , Neuronas Motoras/patología , Mutación Missense/genética , Degeneración Nerviosa/genética , Degeneración Nerviosa/patología , Degeneración Nerviosa/fisiopatología , Médula Espinal/metabolismo , Médula Espinal/patología , Médula Espinal/fisiopatología , Superóxido Dismutasa/metabolismo , Tálamo/metabolismo , Tálamo/patología , Tálamo/fisiopatología , Núcleos del Trigémino/metabolismo , Núcleos del Trigémino/patología , Núcleos del Trigémino/fisiopatología
3.
Eur J Neurosci ; 18(8): 2292-300, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-14622190

RESUMEN

For neuroprotective therapy of neurodegenerative diseases creatine treatment has gained special interest because creatine has been shown to cross the blood-brain barrier, accumulate in the human brain in vivo and cause delayed neuronal cell death in a large number of animal models. Here, we used the pilocarpine model of temporal lobe epilepsy to determine whether creatine administration is able to attenuate the epilepsy-associated decrease in hippocampal N-acetyl aspartate (NAA) concentrations, impairment of mitochondrial function and neuronal cell loss. In vivo1H-NMR spectroscopy showed, in epileptic rats after creatine administration, higher hippocampal NAA concentrations, suggesting improved neuronal survival. However, in vitro observation of hippocampal slices from creatine-treated epileptic rats revealed a more pronounced loss of pyramidal neurons and decrease in activity of mitochondrial enzymes in hippocampal subfields. This indicates that NAA concentrations measured by in vivo1H-NMR spectroscopy reflect alterations of metabolism rather than neuronal cell densities. Our data indicate an adverse effect of creatine on neuronal survival under conditions of enhanced neuronal activity.


Asunto(s)
Ácido Aspártico/análogos & derivados , Ácido Aspártico/metabolismo , Creatina/uso terapéutico , Epilepsia del Lóbulo Temporal/metabolismo , Hipocampo/metabolismo , Neuronas/patología , Animales , Anticonvulsivantes/farmacología , Recuento de Células , Diazepam/farmacología , Modelos Animales de Enfermedad , Epilepsia del Lóbulo Temporal/inducido químicamente , Epilepsia del Lóbulo Temporal/patología , Alimentos Formulados , Hipocampo/patología , Técnicas In Vitro , Espectroscopía de Resonancia Magnética/métodos , Masculino , Agonistas Muscarínicos , Antagonistas Muscarínicos/farmacología , Neuronas/efectos de los fármacos , Pilocarpina , Ratas , Ratas Wistar , Escopolamina/farmacología , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA